Actively Recruiting
Evaluating Intrathecal LTX-002 Versus Placebo in Adults With Amyotrophic Lateral Sclerosis Using Multiple Dose Levels
Led by Leal Therapeutics, Inc · Updated on 2026-08-18
56
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating an investigational medication called LTX-002 in adults with amyotrophic lateral sclerosis ALS. The study focuses on assessing the safety, tolerability, how the body processes the drug, and how the drug affects the body. The trial also examines the impact of LTX-002 on ALS severity by measuring markers in blood and cerebrospinal fluid, as well as participants abilities to move, speak, and breathe. Participants will receive LTX-002 or a placebo via injection into the cerebrospinal fluid through a lumbar puncture. Several dose levels of LTX-002, an antisense oligonucleotide targeting SPTLC1 messenger RNA, will be tested. The study involves nine visits to the study site, including one overnight stay, plus eight telephone or video calls. Procedures include medical history review, physical and neurological exams, ECGs, lung function tests, speech and muscle strength measures, and collection of blood, urine, and cerebrospinal fluid samples. During the study, researchers will monitor safety through various assessments including adverse events, laboratory tests, vital signs, neurological exams, and heart electrical activity from screening to day 169. They will also study the pharmacokinetics of LTX-002 by measuring its levels in cerebrospinal fluid and plasma over time. Participants can expect regular evaluations of ALS symptoms and overall health, with the total study involvement lasting several months.
CONDITIONS
Brief Title
A Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis
Research Team
C
Clinical Trials Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here